Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Lexaria Bioscience Corp. - Common Stock (NQ: LEXX )

1.730 -0.010 (-0.57%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lexaria Bioscience Corp. - Common Stock

< Previous 1 2
...
23 24 25 26 27 28 29 30 Next >
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Lexaria Bioscience (NASDAQ:LEXX) shares increased by 30.28% to $6.41 during Wednesday's pre-market session. The company's market cap stands at $36.7... 
Via Benzinga
Lexaria's DehydraTECHTM-CBD Reduces Arterial Stiffness, Results Confirmed in Human Clinical Study HYPER-H21-2
Results suggest broader applications for DehydraTECH-CBD beyond hypertension KELOWNA, BC / ACCESSWIRE / December 8, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Featured in Virtual Coverage of Benzinga’s Small Cap Conference
Via Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) to Participate in Upcoming Benzinga Global Small Cap Conference
Via CannabisNewsWire
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) to Participate in Upcoming Benzinga Global Small Cap Conference
Via Investor Brand Network
Lexaria Bioscience Embarking on Potentially Pivotal Study to Evaluate DehydraTECH-CBD
Lexaria Bioscience Corp. (NASDAQ: 
Via Benzinga
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Embarking on Potentially Pivotal Study to Evaluate DehydraTECH-CBD
Via CannabisNewsWire
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Embarking on Potentially Pivotal Study to Evaluate DehydraTECH-CBD
Via Investor Brand Network
Lexaria's DehydraTECH(TM) Demonstrates 10-20X Faster Nicotine Delivery in Recent Study
Lexaria Bioscience Corp 
Via Benzinga
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Demonstrates 10-20X Faster Nicotine Delivery in Recent Study
Via CannabisNewsWire
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Demonstrates 10-20X Faster Nicotine Delivery in Recent Study
Via Investor Brand Network
Lexaria Bioscience's DehydraTECH(TM) Drug Delivery Tech Finding Multiple Applications
Lexaria intends to undertake its most ambitious study yet – HYPER-H21-4 – as it pursu... 
Via Benzinga
Lexaria Bioscience Corp. (NASDAQ: LEXX) DehydraTECH(TM) Drug Delivery Technology Finding Multiple Medical Applications
Via Investor Brand Network
Lexaria Bioscience Announces 2022 DehydraTECH(TM) R&D Programs
Lexaria’s 2022 R&D programs are set to include research on hormone replacement, dementia, rheumatoid disease, and diabetes, among other conditions The program builds... 
Via Benzinga
Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces 2022 DehydraTECH(TM) R&D Programs, Including Investigations into Alzheimer’s Disease and Diabetes
Via Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces 2022 DehydraTECH(TM) R&D Programs, Including Investigations into Alzheimer’s Disease and Diabetes
Via CannabisNewsWire
Lexaria Bioscience Corp. Embarks on Ambitious Hypertension Clinical Study
Lexaria has embarked on its HYPER-H21-4 study, its fourth hypertension clinical study, and its most ambitious yet This study builds on the HYPER-H21-1 and HYPER-H21-2 findings,... 
Via Benzinga
Lexaria Bioscience Corp. (NASDAQ: LEXX) Embarks on its Most Ambitious Hypertension Clinical Study Yet: HYPER-H21-4
Via Investor Brand Network
Lexaria Expands 2022 R&D Programs to Evaluate Alzheimer's, Diabetes
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, today announced its plans for several new and ongoing DehydraTECH(TM)-applied R&D programs... 
Via Benzinga
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands 2022 R&D Programs to Evaluate Potential Treatment Options for Alzheimer’s and Diabetes
Via CannabisNewsWire
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands 2022 R&D Programs to Evaluate Potential Treatment Options for Alzheimer’s and Diabetes
Via Investor Brand Network
Lexaria 2022 R&D Programs to Include Investigations into Alzheimer's Disease and Diabetes
KELOWNA, BC / ACCESSWIRE / November 10, 2021 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces its plans for... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Death Intellectual Property
Exposures Death Intellectual Property
Lexaria Bioscience Corp. Commences New Animal Study Evaluating Patented DehydraTECH(TM) Technology's Efficacy in Reducing/Inhibiting Seizure Activity
Lexaria recently announced the commencement of EPIL-A21-1, an animal study to evaluate whether DehydraTECH-CBD h... 
Via Benzinga
Lexaria Bioscience Corp. (NASDAQ: LEXX) Commences New Animal Study Evaluating Patented DehydraTECH(TM) Technology’s Efficacy in Reducing/Inhibiting Seizure Activity; Strengthens IP Portfolio
Via Investor Brand Network
Lexaria Bioscience Corp. to Expand Hypertension Clinical Program Through Most Ambitious Study to Date
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, today announced a significant new study to expand its hypertension clinical program. In addition... 
Via Benzinga
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) to Expand Hypertension Clinical Program Through Most Ambitious Study to Date
Via CannabisNewsWire
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) to Expand Hypertension Clinical Program Through Most Ambitious Study to Date
Via Investor Brand Network
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Glaukos (NYSE:GKOS) stock increased by 25.55% to $56.58 during Wednesday's pre-market session. The market value of their outstanding shares is at $2.6 billion... 
Via Benzinga
Lexaria Announces Ambitious New Hypertension Study HYPER-H21-4
- DehydraTECH-CBD also being evaluated in three other human clinical studies - Positive studies would support Lexaria's regulatory approval plans KELOWNA, BC / ACCESSWIRE / November 3, 2021 / Lexaria... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
Lexaria Bioscience Corp. Begins R&D Program Comparing DehydraTECH-CBD with Generic CBD, Epidiolex
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has begun a new study, EPIL-A21-1, designed to evaluate whether its DehydraTECH(TM)-CBD (“... 
Via Benzinga
< Previous 1 2
...
23 24 25 26 27 28 29 30 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.